Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans
Polaryx Therapeutics Inc. (NASDAQ:PLYX) shares are up on Tuesday as the company has made significant strides in advancing its clinical programs.
The positive movement follows the announcement that Polaryx has selected a contract research organization for its SOTERIA Phase 2 basket trial, which aims to evaluate its lead candidate, PLX-200, across multiple lysosomal storage disorders.
The SOTERIA trial represents a flexible and resource-efficient mechanism for the clinical development of PLX-200.
Polaryx’s selection of a leading contract research organization marks a pivotal milestone as it prepares to initiate the SOTERIA trial in the first half of 2026. The trial is designed to assess the safety, tolerability, and clinical activity of PLX-200 across four different lysosomal storage disorders, with the company having received a safe to proceed letter from the FDA in October 2025.
The SOTERIA trial will incorporate analyses comparing natural history data as a control arm to the treated arm of PLX-200, which is an orally available compound derived from gemfibrozil. This trial is expected to gather crucial data that will inform the future clinical development pathway for PLX-200, potentially leading to conditional marketing authorization if compelling clinical activity is demonstrated.
PLYX Price Action: Polaryx Therapeutics shares were up 46.06% at $3.52 at the time of publication on Tuesday. The stock is trading near its 52-week low of $2.20.
Photo: jittawit21/Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Can raising interest rates tame US inflation? The CPI report sets the tone for the Federal Reserve's decision next week, but tariffs, oil prices, and AI investment may cast doubt on policy effectiveness.
Federal Reserve officials have previously signaled that they are prepared to raise interest rates if inflation does not improve soon. However, some analysts believe that, in hindsight, they may find that the effectiveness of this key policy tool is quite limited in addressing the multiple factors currently driving up prices.
Starbucks: Fleeing China in Disarray, Can the Coffee King Make a Comeback in the US?
Rackspace (RXT.US) joins Nvidia AI cloud computing ecosystem, partners with Palantir to advance “sovereign AI” and AI cloud growth engine
This collaboration will enhance Rackspace's ability to provide and manage Nvidia Blackwell AI computing for regulated enterprises and sovereign entities.
Crypto prices
More
